Therapeutic Efficacy of the Humanized Jaa-F11 Anti-Thomsen-Friedenreich Antibody Constructs H2aL2a and H3L3 in Human Breast and Lung Cancer Xenograft Models

Authors

Diala Ghazal
Fatma Zalzala
John C Fisk
Swetha Tati
Loukia G Karacosta
Susan Morey
James R Olson
Sally Quataert
Grace K Dy
Kate Rittenhouse-Olson

Publication Date

10-19-2022

Journal

Oncotarget

Abstract

The Thomsen-Friedenreich antigen (TF-Ag-α) is found on ~85% of human carcinomas but is cryptic on normal tissue. The humanized highly specific hJAA-F11-H2aL2a and -H3L3 antibodies target TF-Ag-α without binding to TF-Ag-beta (found on surface glycolipids of some normal cells). The relative affinity of H3L3 is 17 times that of H2aL2a, which would seem to favor superior efficacy, however, increased affinity can result in less tumor penetration. To assess the potential therapeutic efficacy of these antibodies, four human cancer- mouse xenograft models were treated with H2aL2a and H3L3. The tumor xenograft models used were human non-small cell lung cancer, H520, and small cell lung cancer, HTB171 in nude mice and human triple negative breast cancer, MDA-MB-231 and HCC1806 in SCID mice. H2aL2a significantly decreased tumor growth in both breast and both lung cancer models. H2aL2a showed statistically equal or better efficacy than H3L3 and has superior production capabilities. These results suggest that H2aL2a may be superior as a naked antibody, as an antibody drug conjugate or as a radiolabeled antibody, however the higher affinity of H3L3 may lead to better efficacy in bi-specific therapies in which the binding is decreased due to the presence of only one TF-Ag-α binding site.

Keywords

Humans, Animals, Mice, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mice, Nude, Heterografts, Mice, SCID, Antigens, Tumor-Associated, Carbohydrate, Immunoconjugates, Antibodies, Glycolipids

Comments

Supplementary Materials

PMID: 36264086